Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
At present, the standard treatment for platinum-resistant ovarian cancer patients is
platinum-free chemotherapy, with poor efficacy and tolerance. The combination of
anti-angiogenic drugs and PARPi can play a synergistic anti-tumor role and achieve good
efficacy in platinum-sensitive recurrent ovarian cancer. This study intends to explore the
safety and effectiveness of anlotinib and niraparib dual therapy in patients with
platinum-resistant recurrent ovarian cancer, fallopian tube cancer, and primary peritoneal
cancer (ovarian cancer).